Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records

Main Article Content

Paul Yamauchi
Chi-Chang Chen
Yao Ding
et al.

Keywords

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Novartis.